Parallelized sample processing and library prep
US-12097501-B2 · Sep 24, 2024 · US
SLCO1B3 genotype
US10094836B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-10094836-B2 |
| Application number | US-52248008-A |
| Country | US |
| Kind code | B2 |
| Filing date | Jan 8, 2008 |
| Priority date | Jan 8, 2007 |
| Publication date | Oct 9, 2018 |
| Grant date | Oct 9, 2018 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The invention relates methods of identifying and predicting inter-patient differences in prognostic prediction for survival in androgen independent prostate cancer. It further related to methods for determining and exploiting such differences to improve medical outcomes. Moreover, it provides methods for determining if a subject has prostate cancer.
First claim
Opening claim text (preview).
What is claimed is: 1. A method of treating a subject having prostate cancer comprising determining a SLCO1B3 genotype status of a subject having prostate cancer, wherein a homozygous 334GG and/or 699AA SLCO1B3 genotype is indicative of a subject that will respond to androgen-deprivation therapy, and wild-type SLCO1B3 genotype is indicative of a patient that is unresponsive to androgen-deprivation therapy; and treating the subject having wild-type SLCO1B3 genotype by discontinuing androgen-deprivation therapy and administering a therapeutically effective amount of an anti-neoplastic agent to the subject, thereby improving survival of the subject having wild-type SLCO1B3 genotype. 2. The method of claim 1 , wherein the anti-neoplastic agent is selected from one or more of docetaxel, cisplatin, cyclophosphamide, doxorubicin, prednisone, 5-FU, trastuzumab, 3G4 travacin, gemcitabine, estramustine, carboplatin, mitomycin, capecitabine, irinotecan, topotecan, vinorelbine, ifosamide, epirubicin, imatinib, gefitinib, erlotinib, cetuximab, bevacizumab, thalidomide, or radiation. 3. The method of claim 1 , wherein the anti-neoplastic agent is docetaxel.
Assignees
Inventors
Classifications
Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism · CPC title
Antineoplastic agents · CPC title
for cancer (immunoassay for cancer G01N33/575) · CPC title
Haplotypes · CPC title
Prognosis of disease development · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US10094836B2 cover?
- The invention relates methods of identifying and predicting inter-patient differences in prognostic prediction for survival in androgen independent prostate cancer. It further related to methods for determining and exploiting such differences to improve medical outcomes. Moreover, it provides methods for determining if a subject has prostate cancer.
- Who is the assignee on this patent?
- Figg William D, Sparreboom Alex, Hamada Akinobu, and 3 more
- What technology area does this patent fall under?
- Primary CPC classification G01N33/57555. Mapped technology areas include Physics.
- When was this patent published?
- Publication date Tue Oct 09 2018 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).